

Clinical Trial Protocol

Iranian Registry of Clinical Trials

31 Jul 2026

Effect of oral Vitamin D Supplementation in recovery of the Patients with Chronic Rhinosinusitis with Nasal Polyps and Vitamin D insufficiency

Protocol summary

Study aim

Determining the efficacy of vitamin D in the recovery of patients with chronic rhinosinusitis with nasal polyps by age/sex/ Duration of treatment/disease grade/Intensity Endoscopic findings/underlying disease/Satisfaction Patient

Design

Clinical trial with control group with parallel and three-way blind and randomized groups on 72 patients. Random number table was used for randomization.

Settings and conduct

The present study will be performed on 72 patients with chronic rhinosinusitis and nasal polyps with moderate vitamin D deficiency referring to Matini Hospital in Kashan in the year of 1399. The patients will be randomly divided into treatment and placebo groups. Vitamin D will be given to the treatment group (50000 iu) per week orally for 8 weeks. The other group will receive a placebo. After 8 weeks of supplementation, both groups will be examined again. The patient, the physician and the analyser are unaware of the type of medication that each patient is taking.

Participants/Inclusion and exclusion criteria

Inclusion: -Definite chronic rhinosinusitis -Nasal polyps - Moderate vitamin D deficiency -Conscious consent
Exclusion: -Taking systemic corticosteroids or other immunomodulatory drugs -Comorbidities and other chronic diseases -Pregnancy -Less than 10 years old of age

Intervention groups

The present study will be performed on 72 patients with chronic rhinosinusitis with nasal polyps and moderate vitamin D deficiency who will be referred to Matini Hospital in Kashan in 1399. These patients will be randomly divided into two groups: treatment and placebo. Vitamin D will be given to the group in oral doses (50000 iu) for 8 weeks and weekly. The other group will also receive a placebo. After 8 weeks of supplementation, the two groups will be reexamined.

Main outcome variables

Improvement of clinical symptoms and endoscopic findings in patients with chronic rhinosinusitis and nasal polyps

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200729048247N1**

Registration date: **2020-09-14, 1399/06/24**

Registration timing: **registered_while_recruiting**

Last update: **2020-09-14, 1399/06/24**

Update count: **0**

Registration date

2020-09-14, 1399/06/24

Registrant information

Name

Leila Kalantari

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 5545 1421

Email address

kalantari-l@kaums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-08-03, 1399/05/13

Expected recruitment end date

2020-10-04, 1399/07/13

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of oral Vitamin D Supplementation in recovery of the Patients with Chronic Rhinosinusitis with Nasal Polyps and Vitamin D insufficiency

Public title

Effect of Vitamin D in Rhinosinusitis with Nasal Polyps

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Chronic rhinosinusitis diagnosed Existence of nasal polyps on examination Vitamin D insufficiency documented in laboratory findings Conscious consent to study

Exclusion criteria:

Use of systemic corticosteroids or other immunosuppressive drugs pregnancy Age less than 10 years Existence of immunological, renal, digestive, glandular and musculoskeletal disorders such as rheumatoid arthritis, immunodeficiency, cystic fibrosis, ciliary dyskinesia, malabsorption

Age

From **10 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

Sample size

Target sample size: **72**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization method was done by permuted blocked randomization first quadropole random block (a.b) was made. Then it was selected by using random number table of a.b letters(72) and based on the entrance number of patient to the study with the prepared random trail one of the a or b letter was excluded. Random sample was selected using <randomizer.ir> website.

Blinding (investigator's opinion)

Triple blinded

Blinding description

In performing this intervention participants and outcome assessors and physician were all unaware of the type of medication the patient was taking. pills presented with exact similar size and color and packing and specific code that was allocated before with random number table.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of kashan University of Medical Sciences

Street address

Kashan University of Medical Sciences. ghotb ravandi blvd. kashan town

City

Kashan

Province

Isfahan

Postal code

5715985191

Approval date

2020-08-03, 1399/05/13

Ethics committee reference number

IR.KAUMS.MEDNT.REC.1399.065

Health conditions studied**1****Description of health condition studied**

Nasal polyps / Chronic rhinosinusitis

ICD-10 code

J33

ICD-10 code description

Nasal polyp / Chronic rhinosinusitis / vitamin D

Primary outcomes**1****Description**

Improvement of disease grade

Timepoint

Before starting the intervention and 8 weeks later

Method of measurement

Endoscopy before starting study and 8 weeks after starting treatment protocol

Secondary outcomes**1****Description**

Serum level of vitamin D

Timepoint

Measurement of serum level of vitamin D at baseline and 8 weeks after the intervention

Method of measurement

Vitamin D blood test

2**Description**

Headache Improvement

Timepoint

Before starting the intervention and 8 weeks later

Method of measurement

Visual analogue scale

3**Description**

Improvement of facial pain

Timepoint

Before starting the intervention and 8 weeks later

Method of measurement

Visual analogue scale

4**Description**

Improvement of hyposmia

Timepoint

Before starting the intervention and 8 weeks later

Method of measurement

Visual analogue scale

5**Description**

Decreasing of post nasal drip

Timepoint

Before starting the intervention and 8 weeks later

Method of measurement

Visual analogue scale

6**Description**

Decreasing of rhinorrhea

Timepoint

Before starting the intervention and 8 weeks later

Method of measurement

Visual analogue scale

7**Description**

Improvement of Nasal obstruction

Timepoint

Before starting the intervention and 8 weeks later

Method of measurement

Visual analogue scale

8**Description**

Improvement of congestion

Timepoint

Before starting the intervention and 8 weeks later

Method of measurement

Visual analogue scale

9**Description**

Improvement of fever

Timepoint

Before starting the intervention and 8 weeks later

Method of measurement

Visual analogue scale

10**Description**

Improvement of Halitosis

Timepoint

Before starting the intervention and 8 weeks later

Method of measurement

Visual analogue scale

11**Description**

Improvement of Drought

Timepoint

Before starting the intervention and 8 weeks later

Method of measurement

Visual analogue scale

12**Description**

Improvement of cough

Timepoint

Before starting the intervention and 8 weeks later

Method of measurement

Visual analogue scale

13**Description**

Improvement of ear pain

Timepoint

Before starting the intervention and 8 weeks later

Method of measurement

Visual analogue scale

Intervention groups**1****Description**

Intervention group: treatment of vitamin D insufficiency with pearl 50000 u vitamin D per week until 8 weeks per oral (Produced by Zahravi Company)

Category

Treatment - Drugs

2

Description

Control group: placebo prescribed(With pearls of the same color, size and shape of vitamin D pearls) per week until 8 weeks per oral(Produced by Zahravi Company)

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Matini Hospital

Full name of responsible person

Leila Kalantari

Street address

Kashan University of Medical Sciences, Ghotb Ravand Blvd, Kashan

City

Kashan

Province

Isfahan

Postal code

8715973474

Phone

+98 31 5545 1421

Email

leilakln284@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Kashan University of Medical Sciences

Full name of responsible person

Dr Amirhossein Ahsani

Street address

Matini Hospital, Amir kabir st, Kashan Town

City

Kashan

Province

Isfahan

Postal code

8715973474

Phone

+98 31 5544 3022

Email

Leilakln284@gmail.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Kashan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Kashan University of Medical Sciences

Full name of responsible person

Leila Kalantari

Position

Medical doctor

Latest degree

Medical doctor

Other areas of specialty/work

General Practitioner

Street address

Kashan University of Medical Sciences, Qotb Ravandi Blvd, Kashan Town

City

Isfahan

Province

Isfahan

Postal code

8715973474

Phone

+98 31 5545 1421

Fax

Email

Kalantari-l@kaums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Kashan University of Medical Sciences

Full name of responsible person

Leila Kalantari

Position

Medical doctor

Latest degree

Medical doctor

Other areas of specialty/work

General Practitioner

Street address

Kashan University of Medical Sciences, Qotb Ravandi Blvd, Kashan Town

City

Isfahan

Province

Isfahan

Postal code

8715973474

Phone

+98 31 5545 1421

Email

LeilakIn284@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Kashan University of Medical Sciences

Full name of responsible person

Leila Kalantari

Position

Med doctor

Latest degree

Medical doctor

Other areas of specialty/work

General Practitioner

Street address

Kashan University of Medical Sciences, Qutb Ravand
Boulevard, Kashan

City

Isfahan

Province

Isfahan

Postal code

8715973474

Phone

+98 31 5545 1421

Email

leilakIn284@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

No - There is not a plan to make this available

Title and more details about the data/document

Any detail going to published

When the data will become available and for how long

starting 2 months after publication

To whom data/document is available

Any scientific and collegiate institutions

Under which criteria data/document could be used

Any analysis allowed

From where data/document is obtainable

leilakIn284@gmail.com Leila kalantari

What processes are involved for a request to access data/document

About 1 month after request with email

Comments